ChemLex Raises $45M to Expand AI Drug Discovery in Singapore.

ChemLex Raises $45 Million to Advance AI-Driven Drug Discovery

ChemLex has raised $45 million in new funding. The round was led by Granite Asia. It marks a milestone for the fast-growing AI-for-science startup. The company was founded in 2022. It aims to transform chemical discovery through artificial intelligence and robotics.

ChemLex now operates from its new global headquarters in Singapore. It also unveiled a fully automated, self-driving chemistry laboratory. The facility represents a major shift in drug discovery methods. It replaces slow manual processes with continuous robotic experiments. It creates cleaner data. It also speeds up a historically long development pipeline.

The raise strengthens Singapore’s role as a centre for advanced science and deep-tech innovation. It also positions ChemLex to compete globally in next-generation pharmaceutical research.

A New Type of Laboratory Built for Constant Discovery

The heart of ChemLex’s operation is its autonomous chemistry system. It runs non-stop. It performs experiments with minimal human input. It captures data in real time. It removes the gaps seen in traditional chemistry, where each experiment takes manual setup, execution, and review.

The company states that the system can gather a day’s worth of data that equals three years of traditional lab work. This single difference changes the pace of discovery. It also changes how new molecules are designed and selected.

The platform uses robotics to plan, run, and analyse chemical reactions. This reduces human error. It increases reproducibility. It gives chemists more time for high-value work such as analysis and strategy.

ChemLex believes this model is the future of chemical research. It compresses months of synthesis into weeks. It cuts the cost of chemical exploration. It creates stable, predictable workflows.

Singapore Becomes the Centre of ChemLex’s Global Mission

Singapore gives ChemLex more than a headquarters. It provides access to talent, research partners, and global pharmaceutical companies. The city-state is home to a mature biomedical science ecosystem. It employs tens of thousands of specialists. It also continues to expand its role as a research hub.

ChemLex’s founder and Chief Executive Officer, Sean Lin, says that Singapore’s environment strengthens their mission. It gives the company the platform to scale quickly. It also positions the firm close to global partners that depend on rapid drug development.

Singapore’s Economic Development Board welcomed the company. It views autonomous chemistry as aligned with the country’s advanced manufacturing strategy. It also sees strong potential for collaboration with research institutes.

ChemLex’s arrival adds to Singapore’s focus on AI in drug discovery. This national priority is part of the country’s next phase of public research investment.

More News: Airwallex Secures $330M Series G at $8B Valuation, Expands to San Francisco and Accelerates AI Finance

Funding to Accelerate Hiring and Expand Research Capacity

The new $45 million will fuel hiring in Singapore. ChemLex plans to bring in more hardware and software engineers. It will also expand its team of chemists. These teams will support pharmaceutical and materials science clients. They will also build next-generation versions of the autonomous chemistry platform.

ChemLex already serves more than 70 customers worldwide. Six of these are among the world’s top ten pharmaceutical companies. Demand for faster molecule discovery continues to rise. AI-powered drug discovery is projected to grow sharply in the next decade.

ChemLex aims to build a global network of automated labs. It hopes to duplicate its Shanghai facility in other regions. Each facility would operate with high-throughput robotics and AI-powered decision engines.

The company stresses that its AI models are trained only on internal data. Customer information is protected by strict isolation. ChemLex views intellectual property protection as a core part of its business.

The Foundation of an Autonomous Discovery Engine

The company’s AI platform handles several critical tasks. It screens molecular options. It proposes new synthesis routes. It predicts reaction outcomes. It selects optimal conditions for each experiment. It also learns from every outcome produced by the robotic systems.

This loop of design, execution, and analysis forms the core of the self-driving lab. The platform can run more than 800 reactions every day. It operates without breaks. It reduces manual work by roughly 90 percent. It allows teams to scale research at levels no traditional lab can match.

ChemLex believes this approach solves long-standing issues in chemical research. Manual work often slows progress. Human variability can distort results. Traditional workflows create bottlenecks and limits on how many experiments can be performed.

The new model removes these limits. It produces cleaner data. It improves reproducibility. It compresses timelines that once stretched over years.

Strategic Partnerships and a Growing Role in Global Drug Development

ChemLex has also signed a memorandum of understanding with Singapore’s Experimental Drug Development Centre. The partnership aims to accelerate small-molecule drug discovery. It uses advanced automation to cut timelines and deliver new treatment options faster.

The company has also joined the Pharmaceutical Innovation Programme Singapore. This grouping brings together industry partners and universities. It looks to develop new technology for chemical manufacturing.

Investors believe ChemLex sits at the centre of one of the most important industrial shifts of the decade. Granite Asia says deep-tech platforms like ChemLex will reshape supply chains. They will shorten development cycles. They will unlock new economic value.

ChemLex appears set to play a role in that shift. Its tools address the root cause of slow discovery. They replace manual lab work with fully autonomous systems. They offer a model that could influence global pharmaceutical science for years to come.